Article
A randomized phase II trial comparing chemoimmunotherapy with or without bevacizumab in previously untreated patients with chronic lymphocytic leukemia.
Oncotarget - 29 Nov 2016
Kay Neil E, Strati Paolo, LaPlant Betsy R, Leis Jose F, Nikcevich Daniel, Call Timothy G, Pettinger Adam M, Lesnick Connie E, Hanson Curtis A, Shanafelt Tait D
Abstract excerpt
Bevacizumab is a monoclonal antibody targeting vascular endothelial growth factor (VEGF) with in vitro pro-apoptotic and antiangiogenic effects on chronic lymphocytic leukemia (CLL) cells. As monotherapy in patients with CLL, it has no clinical activity. Here we report the results of an open-label, randomized phase II trial comparing the combination of pentostatin, cyclophosphamide and rituximab (PCR) either...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.